Ovarian cancer: Diagnosis and treatment strategies (Review)
- Authors:
- Xuejiao Li
- Zhuocheng Li
- Huiling Ma
- Xinwei Li
- Hongxiao Zhai
- Xixi Li
- Xiaofei Cheng
- Xiaohui Zhao
- Zhilong Zhao
- Zhenhua Hao
-
Affiliations: Department of Basic Medicine Science, Sanquan College of Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China, Department of Ultrasound, Zhengzhou First People's Hospital, Zhengzhou, Henan 450004, P.R. China - Published online on: July 18, 2024 https://doi.org/10.3892/ol.2024.14574
- Article Number: 441
-
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Freimund AE, Beach JA, Christie EL and Bowtell DDL: Mechanisms of drug resistance in high-grade serous ovarian cancer. Hematol Oncol Clin North Am. 32:983–996. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Borch TH, Andersen R, Ellebaek E, Met Ö, Donia M and Svane IM: Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma. J Immunother Cancer. 8:e0006682020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang W, Shi F, Kong Y, Li Y, Sheng C, Wang S and Wang Q: Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer. Cancer Med. 11:676–691. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Wang M, Herbst RS and Boshoff C: Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 27:1345–1356. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Soberanis Pina P and Lheureux S: Overcoming PARP inhibitor resistance in ovarian cancer. Int J Gynecol Cancer. 33:364–376. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Cheasley D, Nigam A, Zethoven M, Hunter S, Etemadmoghadam D, Semple T, Allan P, Carey MS, Fernandez ML, Dawson A, et al: Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities. J Pathol. 253:41–54. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Flaum N, Crosbie EJ, Edmondson RJ, Smith MJ and Evans DG: Epithelial ovarian cancer risk: A review of the current genetic landscape. Clin Genet. 97:54–63. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Garziera M, Cecchin E, Canzonieri V, Sorio R, Giorda G, Scalone S, De Mattia E, Roncato R, Gagno S, Poletto E, et al: Identification of novel somatic TP53 mutations in patients with high-grade serous ovarian cancer (HGSOC) using next-generation sequencing (NGS). Int J Mol Sci. 19:15102018. View Article : Google Scholar : PubMed/NCBI | |
|
Bolton KL, Chen D, Corona de la Fuente R, Fu Z, Murali R, Köbel M, Tazi Y, Cunningham JM, Chan ICC, Wiley BJ, et al: Molecular subclasses of clear cell ovarian carcinoma and their impact on disease behavior and outcomes. Clin Cancer Res. 28:4947–4956. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Wei X, Bai G, Huang X, Hu S, Mao H and Liu P: Identification of three potential prognostic genes in platinum-resistant ovarian cancer via integrated bioinformatics analysis. Cancer Manag Res. 13:8629–8646. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Samborski A, Miller MC, Blackman A, MacLaughlan-David S, Jackson A, Lambert-Messerlian G, Rowswell-Turner R and Moore RG: HE4 and CA125 serum biomarker monitoring in women with epithelial ovarian cancer. Tumour Biol. 44:205–213. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Turner MA, Lwin TM, Amirfakhri S, Nishino H, Hoffman RM, Yazaki PJ and Bouvet M: The use of fluorescent anti-CEA antibodies to label, resect and treat cancers: A review. Biomolecules. 11:18192021. View Article : Google Scholar : PubMed/NCBI | |
|
Anastasi E, Farina A, Granato T, Colaiacovo F, Pucci B, Tartaglione S and Angeloni A: Recent insight about HE4 role in ovarian cancer oncogenesis. Int J Mol Sci. 24:104792023. View Article : Google Scholar : PubMed/NCBI | |
|
Ali FT, Soliman RM, Hassan NS, Ibrahim AM, El-Gizawy MM, Mandoh AAY and Ibrahim EA: Sensitivity and specificity of microRNA-204, CA125, and CA19.9 as biomarkers for diagnosis of ovarian cancer. PLoS One. 17:e02723082022. View Article : Google Scholar : PubMed/NCBI | |
|
Lv J and Li P: Mesothelin as a biomarker for targeted therapy. Biomark Res. 7:182019. View Article : Google Scholar : PubMed/NCBI | |
|
Rath A, Mitra S, Adhya AK and Majumdar SKD: Immature teratoma with very high AFP levels. Eur J Obstet Gynecol Reprod Biol X. 16:1001702022.PubMed/NCBI | |
|
Wu Y, Xu S, Cheng S, Yang J and Wang Y: Clinical application of PARP inhibitors in ovarian cancer: From molecular mechanisms to the current status. J Ovarian Res. 16:62023. View Article : Google Scholar : PubMed/NCBI | |
|
Dilawari A, Shah M, Ison G, Gittleman H, Fiero MH, Shah A, Hamed SS, Qiu J, Yu J, Manheng W, et al: FDA approval summary: Mirvetuximab soravtansine-gynx for FRα-positive, platinum-resistant ovarian cancer. Clin Cancer Res. 29:3835–3840. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Borcoman E, Santana Dos Santos E, Genestie C, Pautier P, Lacroix L, Caputo SM, Cabaret O, Guillaud-Bataille M, Michels J, Auguste A, et al: Combined tumor-based BRCA1/2 and TP53 mutation testing in ovarian cancer. Int J Mol Sci. 24:115702023. View Article : Google Scholar : PubMed/NCBI | |
|
Magliacane G, Brunetto E, Calzavara S, Bergamini A, Pipitone GB, Marra G, Redegalli M, Grassini G, Rabaiotti E, Taccagni G, et al: Locally Performed HRD testing for ovarian cancer? Yes, we can! Cancers (Basel). 15:422022.PubMed/NCBI | |
|
Grafodatskaya D, O'Rielly DD, Bedard K, Butcher DT, Howlett CJ, Lytwyn A, McCready E, Parboosingh J, Spriggs EL, Vaags AK and Stockley TL: Practice guidelines for BRCA1/2 tumour testing in ovarian cancer. J Med Genet. 59:727–736. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Umemura S, Sowa Y, Iizumi Y, Kitawaki J and Sakai T: Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS-mutated ovarian cancer cells with high AXL expression. Cancer Sci. 111:2052–2061. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Dochez V, Caillon H, Vaucel E, Dimet J, Winer N and Ducarme G: Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. J Ovarian Res. 12:282019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang M, Cheng S, Jin Y, Zhao Y and Wang Y: Roles of CA125 in diagnosis, prediction, and oncogenesis of ovarian cancer. Biochim Biophys Acta Rev Cancer. 1875:1885032021. View Article : Google Scholar : PubMed/NCBI | |
|
Chen F, Shen J, Wang J, Cai P and Huang Y: Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: Diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. Cancer Manag Res. 10:1313–1318. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Barani M, Bilal M, Sabir F, Rahdar A and Kyzas GZ: Nanotechnology in ovarian cancer: Diagnosis and treatment. Life Sci. 266:1189142021. View Article : Google Scholar : PubMed/NCBI | |
|
Hurley LC, Levin NK, Chatterjee M, Coles J, Muszkat S, Howarth Z, Dyson G and Tainsky MA: Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53. Cancer Biomark. 27:407–421. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lekka S, Psomiadou V, Panoskaltsis T, Tsouma E, Novkovic N, Trihia H, Tzaida O, Korfias D, Giannakas P, Iavazzo C, et al: CytoSaLPs score: A promising new tool for the detection and screening of extrauterine high grade serous carcinoma. BMC Cancer. 23:1572023. View Article : Google Scholar : PubMed/NCBI | |
|
Liu S, Yuan L, Li J, Liu Y, Wang H and Ren X: circDENND4C, a novel serum marker for epithelial ovarian cancer, acts as a tumor suppressor by downregulating miR-200b/c. Ann Med. 55:908–919. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Chae CS, Sandoval TA, Hwang SM, Park ES, Giovanelli P, Awasthi D, Salvagno C, Emmanuelli A, Tan C, Chaudhary V, et al: Tumor-derived lysophosphatidic acid blunts protective type I interferon responses in ovarian cancer. Cancer Discov. 12:1904–1921. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Xu M, Zhang D, Xu X, Zhang J and Jiang G: Application of blood extracellular vesicle miRNA in early diagnosis of ovarian cancer. Chinese Patent Application Publication CN117802228A. Filed. September 30–2022. | |
|
Bansal A, Srinivasan R, Rohilla M, Sundaram A, Rai B, Rajwanshi A, Suri V, Saha SC, Gupta N, Gupta P and Dey P: Morphologic and immunocytochemical features of high-grade serous carcinoma of ovary in ascitic fluid effusion and fine-needle aspiration cytology. Am J Clin Pathol. 154:103–114. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Asante DB, Calapre L, Ziman M, Meniawy TM and Gray ES: Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time? Cancer Lett. 468:59–71. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Campos-Carrillo A, Weitzel JN, Sahoo P, Rockne R, Mokhnatkin JV, Murtaza M, Gray SW, Goetz L, Goel A, Schork N and Slavin TP: Circulating tumor DNA as an early cancer detection tool. Pharmacol Ther. 207:1074582020. View Article : Google Scholar : PubMed/NCBI | |
|
Kim YM, Lee SW, Lee YJ, Lee HY, Lee JE and Choi EK: Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma. J Gynecol Oncol. 30:e322019. View Article : Google Scholar : PubMed/NCBI | |
|
Lu Y and Li L: The prognostic value of circulating tumor DNA in ovarian cancer: A meta-analysis. Technol Cancer Res Treat. 20:153303382110437842021. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu JW, Charkhchi P and Akbari MR: Potential clinical utility of liquid biopsies in ovarian cancer. Mol Cancer. 21:1142022. View Article : Google Scholar : PubMed/NCBI | |
|
Buza N: Immunohistochemistry in gynecologic carcinomas: Practical update with diagnostic and clinical considerations based on the 2020 WHO classification of tumors. Semin Diagn Pathol. 39:58–77. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Hosseini MS, Amiri F, Rezapour M, Ashraf Ganjoie T, Farzaneh F, Arab M, Talayeh M, Beheshti Rooy R and Hadi F: Evaluation of the cutoff point and diagnostic value of the neutrophil-to-lymphocyte ratio in predicting ovarian cancer compared to pathological findings. Asian Pac J Cancer Prev. 25:971–976. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L: Prognostic effect of programmed death-ligand 1 (PD-L1) in ovarian cancer: A systematic review, meta-analysis and bioinformatics study. J Ovarian Res. 12:372019. View Article : Google Scholar : PubMed/NCBI | |
|
Olbrecht S, Busschaert P, Qian J, Vanderstichele A, Loverix L, Van Gorp T, Van Nieuwenhuysen E, Han S, Van den Broeck A, Coosemans A, et al: High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: Specific cell subtypes influence survival and determine molecular subtype classification. Genome Med. 13:1112021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu C, Zhang Y, Li X and Wang D: Ovarian cancer-specific dysregulated genes with prognostic significance: scRNA-Seq with bulk RNA-Seq data and experimental validation. Ann N Y Acad Sci. 1512:154–173. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Nagasawa S, Ikeda K, Horie-Inoue K, Sato S, Takeda S, Hasegawa K and Inoue S: Identification of novel mutations of ovarian cancer-related genes from RNA-sequencing data for Japanese epithelial ovarian cancer patients. Endocr J. 67:219–229. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Shih AJ, Menzin A, Whyte J, Lovecchio J, Liew A, Khalili H, Bhuiya T, Gregersen PK and Lee AT: Identification of grade and origin specific cell populations in serous epithelial ovarian cancer by single cell RNA-seq. PLoS One. 13:e02067852018. View Article : Google Scholar : PubMed/NCBI | |
|
Wang J, Dean DC, Hornicek FJ, Shi H and Duan Z: RNA sequencing (RNA-Seq) and its application in ovarian cancer. Gynecol Oncol. 152:194–201. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Huang D, Chowdhury S, Wang H, Savage SR, Ivey RG, Kennedy JJ, Whiteaker JR, Lin C, Hou X, Oberg AL, et al: Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer. Cell Rep Med. 2:1004712021. View Article : Google Scholar : PubMed/NCBI | |
|
Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, Normanno N, Scarpa A, Robson M, Meric-Bernstam F, et al: Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: A report from the ESMO precision medicine working group. Ann Oncol. 31:1491–1505. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Huhtaniemi I, Hovatta O, La Marca A, Livera G, Monniaux D, Persani L, Heddar A, Jarzabek K, Laisk-Podar T, Salumets A, et al: Advances in the molecular pathophysiology, genetics, and treatment of primary ovarian insufficiency. Trends Endocrinol Metab. 29:400–419. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Dou Z, Qiu C, Zhang X, Yao S, Zhao C, Wang Z, Chu R, Chen J, Chen Z, Li R, et al: HJURP promotes malignant progression and mediates sensitivity to cisplatin and WEE1-inhibitor in serous ovarian cancer. Int J Biol Sci. 18:1188–1210. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu Z, Chen Z, Wang M, Zhang M, Chen Y, Yang X, Zhou C, Liu Y, Hong L and Zhang L: Detection of plasma exosomal miRNA-205 as a biomarker for early diagnosis and an adjuvant indicator of ovarian cancer staging. J Ovarian Res. 15:272022. View Article : Google Scholar : PubMed/NCBI | |
|
Gong G, Lin T and Yuan Y: Integrated analysis of gene expression and DNA methylation profiles in ovarian cancer. J Ovarian Res. 13:302020. View Article : Google Scholar : PubMed/NCBI | |
|
Chen D, Wu Y, Tilley RD and Gooding JJ: Rapid and ultrasensitive electrochemical detection of DNA methylation for ovarian cancer diagnosis. Biosens Bioelectron. 206:1141262022. View Article : Google Scholar : PubMed/NCBI | |
|
Hooda J, Novak M, Salomon MP, Matsuba C, Ramos RI, MacDuffie E, Song M, Hirsch MS, Lester J, Parkash V, et al: Early loss of histone H2B monoubiquitylation alters chromatin accessibility and activates key immune pathways that facilitate progression of ovarian cancer. Cancer Res. 79:760–772. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Peng B, Li J, Yan Y, Liu Y, Liang Q, Liu W, Thakur A, Zhang K, Xu Z, Wang J and Zhang F: Non-coding RNAs: The recently accentuated molecules in the regulation of cell autophagy for ovarian cancer pathogenesis and therapeutic response. Front Pharmacol. 14:11620452023. View Article : Google Scholar : PubMed/NCBI | |
|
Singh A, Gupta S, Badarukhiya JA and Sachan M: Detection of aberrant methylation of HOXA9 and HIC1 through multiplex MethyLight assay in serum DNA for the early detection of epithelial ovarian cancer. Int J Cancer. 147:1740–1752. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Washington CR, Richardson DL and Moore KN: Olaparib in the treatment of ovarian cancer. Future Oncol. 15:3435–3449. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Shirley M: Rucaparib: A review in ovarian cancer. Target Oncol. 14:237–246. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Essel KG and Moore KN: Niraparib for the treatment of ovarian cancer. Expert Rev Anticancer Ther. 18:727–733. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Lee A: Fuzuloparib: First approval. Drugs. 81:1221–1226. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Luo L and Keyomarsi K: PARP inhibitors as single agents and in combination therapy: The most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Expert Opin Investig Drugs. 31:607–631. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Guan LY and Lu Y: New developments in molecular targeted therapy of ovarian cancer. Discov Med. 26:219–229. 2018.PubMed/NCBI | |
|
Matulonis UA, Lorusso D, Oaknin A, Pignata S, Dean A, Denys H, Colombo N, Van Gorp T, Konner JA, Marin MR, et al: Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: Results from the SORAYA study. J Clin Oncol. 41:2436–2445. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Smith M and Pothuri B: Appropriate selection of PARP inhibitors in ovarian cancer. Curr Treat Options Oncol. 23:887–903. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Lee CK, Friedlander ML, Tjokrowidjaja A, Ledermann JA, Coleman RL, Mirza MR, Matulonis UA, Pujade-Lauraine E, Bloomfield R, Goble S, et al: Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. Cancer. 127:2432–2441. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Mirza MR, Coleman RL, González-Martín A, Moore KN, Colombo N, Ray-Coquard I and Pignata S: The forefront of ovarian cancer therapy: update on PARP inhibitors. Ann Oncol. 31:1148–1159. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lheureux S, Braunstein M and Oza AM: Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J Clin. 69:280–304. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, et al: Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 22:620–631. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Nakazawa H, Nagao S, Narita M, Shibutani T, Jimi T, Yano H, Kitai M, Shiozaki T and Yamaguchi S: Effect of prior olaparib maintenance therapy for platinum sensitive recurrent ovarian cancer on response to subsequent platinum-based chemotherapy. J Obstet Gynaecol Res. 48:1248–1254. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Moore DC, Ringley JT and Patel J: Rucaparib: A Poly(ADP-Ribose) polymerase inhibitor for BRCA-mutated relapsed ovarian cancer. J Pharm Pract. 32:219–224. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Ledermann JA, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp AR, Scambia G, et al: Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): Post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 21:710–722. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, et al: Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. J Clin Oncol. 37:2968–2973. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Lee A: Niraparib: A review in first-line maintenance therapy in advanced ovarian cancer. Target Oncol. 16:839–845. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
No authors listed. Niraparib for ovarian cancer. Aust Prescr. 44:208–209. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Gupta S, Nag S, Aggarwal S, Rauthan A and Warrier N: Maintenance therapy for recurrent epithelial ovarian cancer: Current therapies and future perspectives-a review. J Ovarian Res. 12:1032019. View Article : Google Scholar : PubMed/NCBI | |
|
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, et al: Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med. 381:2416–2428. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Boussios S, Karathanasi A, Cooke D, Neille C, Sadauskaite A, Moschetta M, Zakynthinakis-Kyriakou N and Pavlidis N: PARP inhibitors in ovarian cancer: The route to ‘Ithaca’. Diagnostics (Basel). 9:552019. View Article : Google Scholar : PubMed/NCBI | |
|
Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ Jr, Feltmate CM, Nucci MR, Swisher EM, Nguyen H, et al: Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. Cancer Discov. 8:1404–1421. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kopper O, de Witte CJ, Lõhmussaar K, Valle-Inclan JE, Hami N, Kester L, Balgobind AV, Korving J, Proost N, Begthel H, et al: An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 25:838–849. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R and Chinot OL: Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 86:1020172020. View Article : Google Scholar : PubMed/NCBI | |
|
Nakai H and Matsumura N: The roles and limitations of bevacizumab in the treatment of ovarian cancer. Int J Clin Oncol. 27:1120–1126. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
O'Malley DM: New Therapies for ovarian cancer. J Natl Compr Canc Netw. 17:619–621. 2019. | |
|
Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, Bookman MA, Fleming GF, Huang H, Homesley HD, et al: Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol. 37:2317–2328. 2019. View Article : Google Scholar | |
|
Cui Q, Hu Y, Ma D and Liu H: A retrospective observational study of anlotinib in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer. Drug Des Devel Ther. 15:339–347. 2021. View Article : Google Scholar | |
|
Wei Y, Erfani S, Schweer D, de Gouvea R, Qadir J, Shi J, Cheng K, Wu D, Craven R, Wu Y, et al: Targeting receptor tyrosine kinases in ovarian cancer: Genomic dysregulation, clinical evaluation of inhibitors, and potential for combinatorial therapies. Mol Ther Oncolytics. 28:293–306. 2023. View Article : Google Scholar | |
|
Ray-Coquard I, Cibula D, Mirza MR, Reuss A, Ricci C, Colombo N, Koch H, Goffin F, González-Martin A, Ottevanger PB, et al: Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. Int J Cancer. 146:439–448. 2020. View Article : Google Scholar | |
|
Ledermann JA, Embleton-Thirsk AC, Perren TJ, Jayson GC, Rustin GJS, Kaye SB, Hirte H, Oza A, Vaughan M, Friedlander M, et al: Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): Overall survival results of a phase III randomised trial. ESMO Open. 6:1000432021. View Article : Google Scholar | |
|
Vergote I, du Bois A, Floquet A, Rau J, Kim JW, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Colombo N, et al: Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. Gynecol Oncol. 155:186–191. 2019. View Article : Google Scholar | |
|
Kuroki L and Guntupalli SR: Treatment of epithelial ovarian cancer. BMJ. 371:m37732020. View Article : Google Scholar | |
|
Zhou AP, Bai Y, Song Y, Luo H, Ren XB, Wang X, Shi B, Fu C, Cheng Y, Liu J, et al: Anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma: A randomized phase II clinical trial. Oncologist. 24:e702–e708. 2019. View Article : Google Scholar | |
|
Morrison J, Thoma C, Goodall RJ, Lyons TJ, Gaitskell K, Wiggans AJ and Bryant A: Epidermal growth factor receptor blockers for the treatment of ovarian cancer. Cochrane Database Syst Rev. 10:CD0079272018. | |
|
Chilimoniuk Z, Rocka A, Stefaniak M, Tomczyk Ż, Jasielska F, Madras D and Filip A: Molecular methods for increasing the effectiveness of ovarian cancer treatment: A systematic review. Future Oncol. 18:1627–1650. 2022. View Article : Google Scholar | |
|
Voigtlaender M, Schneider-Merck T and Trepel M: Lapatinib. Recent Results Cancer Res. 211:19–44. 2018. View Article : Google Scholar | |
|
Ediriweera MK, Tennekoon KH and Samarakoon SR: Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance. Semin Cancer Biol. 59:147–160. 2019. View Article : Google Scholar | |
|
Ren M, Zhao H, Gao Y, Chen Q, Zhao X and Yue W: NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer. J Ovarian Res. 16:172023. View Article : Google Scholar | |
|
Siegel RL, Miller KD, Wagle NS and Jemal A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023. View Article : Google Scholar | |
|
Hu X, Xia M, Wang J, Yu H, Chai J, Zhang Z, Sun Y, Su J and Sun L: Dual PI3K/mTOR inhibitor PKI-402 suppresses the growth of ovarian cancer cells by degradation of Mcl-1 through autophagy. Biomed Pharmacother. 129:1103972020. View Article : Google Scholar | |
|
Hendrikse CSE, Theelen PMM, van der Ploeg P, Westgeest HM, Boere IA, Thijs AMJ, Ottevanger PB, van de Stolpe A, Lambrechts S, Bekkers RLM and Piek JMJ: The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol. 171:83–94. 2023. View Article : Google Scholar | |
|
Degirmenci U, Wang M and Hu J: Targeting aberrant RAS/RAF/MEK/ERK signaling for cancer therapy. Cells. 9:1982020. View Article : Google Scholar | |
|
Vena F, Jia R, Esfandiari A, Garcia-Gomez JJ, Rodriguez-Justo M, Ma J, Syed S, Crowley L, Elenbaas B, Goodstal S, et al: MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models. Oncotarget. 9:11592–11603. 2018. View Article : Google Scholar | |
|
Scaranti M, Cojocaru E, Banerjee S and Banerji U: Exploiting the folate receptor α in oncology. Nat Rev Clin Oncol. 17:349–359. 2020. View Article : Google Scholar | |
|
Heo YA: Mirvetuximab soravtansine: First approval. Drugs. 83:265–273. 2023. View Article : Google Scholar | |
|
Rodriguez GM, Yakubovich E and Vanderhyden BC: Unveiling the immunogenicity of ovarian tumors as the crucial catalyst for therapeutic success. Cancers (Basel). 15:56942023. View Article : Google Scholar | |
|
Guo Q, Yang Q, Li J, Liu G, Nikoulin I and Jia S: Advanced clinical trials of dendritic cell vaccines in ovarian cancer. J Investig Med. 68:1223–1227. 2020. View Article : Google Scholar | |
|
Calmeiro J, Carrascal MA, Tavares AR, Ferreira DA, Gomes C, Falcão A, Cruz MT and Neves BM: Dendritic cell vaccines for cancer immunotherapy: The role of human conventional type 1 dendritic cells. Pharmaceutics. 12:1582020. View Article : Google Scholar | |
|
Dafni U, Martín-Lluesma S, Balint K, Tsourti Z, Vervita K, Chenal J, Coukos G, Zaman K, Sarivalasis A and Kandalaft LE: Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis. Eur J Cancer. 142:63–82. 2021. View Article : Google Scholar | |
|
Manning-Geist BL, Gnjatic S, Aghajanian C, Konner J, Kim SH, Sarasohn D, Soldan K, Tew WP, Sarlis NJ, Zamarin D, et al: Phase I study of a multivalent WT1 peptide vaccine (galinpepimut-S) in combination with nivolumab in patients with WT1-expressing ovarian cancer in second or third remission. Cancers (Basel). 15:14582023. View Article : Google Scholar | |
|
Zhao Z, Ortega-Rivera OA, Chung YH, Simms A and Steinmetz NF: A co-formulated vaccine of irradiated cancer cells and cowpea mosaic virus improves ovarian cancer rejection. J Mater Chem B. 11:5429–5441. 2023. View Article : Google Scholar | |
|
Xu H, Zhao F, Wu D, Zhang Y, Bao X, Shi F, Cai Y and Dou J: Eliciting effective tumor immunity against ovarian cancer by cancer stem cell vaccination. Biomed Pharmacother. 161:1145472023. View Article : Google Scholar | |
|
Liu X, Shi Y, Zhang D, Zhou Q, Liu J, Chen M, Xu Y, Zhao J, Zhong W and Wang M: Risk factors for immune-related adverse events: What have we learned and what lies ahead? Biomark Res. 9:792021. View Article : Google Scholar | |
|
Zamarin D, Burger RA, Sill MW, Powell DJ Jr, Lankes HA, Feldman MD, Zivanovic O, Gunderson C, Ko E, Mathews C, et al: Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: An NRG oncology study. J Clin Oncol. 38:1814–1823. 2020. View Article : Google Scholar | |
|
Peyraud F and Italiano A: Combined PARP inhibition and immune checkpoint therapy in solid tumors. Cancers (Basel). 12:15022020. View Article : Google Scholar | |
|
Disis ML, Taylor MH, Kelly K, Beck JT, Gordon M, Moore KM, Patel MR, Chaves J, Park H, Mita AC, et al: Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: Phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 5:393–401. 2019. View Article : Google Scholar | |
|
Xin Yu J, Hodge JP, Oliva C, Neftelinov ST, Hubbard-Lucey VM and Tang J: Trends in clinical development for PD-1/PD-L1 inhibitors. Nat Rev Drug Discov. 19:163–164. 2020. View Article : Google Scholar | |
|
Komura N, Mabuchi S, Shimura K, Yokoi E, Kozasa K, Kuroda H, Takahashi R, Sasano T, Kawano M, Matsumoto Y, et al: The role of myeloid-derived suppressor cells in increasing cancer stem-like cells and promoting PD-L1 expression in epithelial ovarian cancer. Cancer Immunol Immunother. 69:2477–2499. 2020. View Article : Google Scholar | |
|
Lee JY, Kim JW, Lim MC, Kim S, Kim HS, Choi CH, Yi JY, Park SY and Kim BG; KGOG investigators, : A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: A Korean gynecologic oncology group study (KGOG 3046), TRU-D. J Gynecol Oncol. 30:e1122019. View Article : Google Scholar | |
|
Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB and Peng G: PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 79:311–319. 2019. View Article : Google Scholar | |
|
Brewer M, Angioli R, Scambia G, Lorusso D, Terranova C, Panici PB, Raspagliesi F, Scollo P, Plotti F, Ferrandina G, et al: Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study. Gynecol Oncol. 156:523–529. 2020. View Article : Google Scholar | |
|
Liu J, Gaillard S, Hendrickson AW, Moroney J, Yeku O, Diver E, Gunderson C, Arend R, Ratner E, Samnotra V, et al: An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): Cohort A of the OPAL trial. Gynecol Oncol. 162 (Suppl 1):S17–S18. 2021. View Article : Google Scholar | |
|
Marin-Acevedo JA, Kimbrough EO and Lou Y: Next generation of immune checkpoint inhibitors and beyond. J Hematol Oncol. 14:452021. View Article : Google Scholar | |
|
Ochoa de Olza M, Navarro Rodrigo B, Zimmermann S and Coukos G: Turning up the heat on non-immunoreactive tumours: Opportunities for clinical development. Lancet Oncol. 21:e419–e430. 2020. View Article : Google Scholar | |
|
Kim E, Ahn H and Park H: A review on the role of gut microbiota in immune checkpoint blockade therapy for cancer. Mamm Genome. 32:223–231. 2021. View Article : Google Scholar | |
|
Dafni U, Michielin O, Lluesma SM, Tsourti Z, Polydoropoulou V, Karlis D, Besser MJ, Haanen J, Svane IM, Ohashi PS, et al: Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: A systematic review and meta-analysis. Ann Oncol. 30:1902–1913. 2019. View Article : Google Scholar | |
|
Yan W, Hu H and Tang B: Advances Of chimeric antigen receptor T cell therapy in ovarian cancer. Onco Targets Ther. 12:8015–8022. 2019. View Article : Google Scholar | |
|
Fucà G, Reppel L, Landoni E, Savoldo B and Dotti G: Enhancing chimeric antigen receptor T-cell efficacy in solid tumors. Clin Cancer Res. 26:2444–2451. 2020. View Article : Google Scholar | |
|
Zhang XW, Wu YS, Xu TM and Cui MH: CAR-T cells in the treatment of ovarian cancer: A promising cell therapy. Biomolecules. 13:4652023. View Article : Google Scholar | |
|
Wu JWY, Dand S, Doig L, Papenfuss AT, Scott CL, Ho G and Ooi JD: T-cell receptor therapy in the treatment of ovarian cancer: A mini review. Front Immunol. 12:6725022021. View Article : Google Scholar | |
|
Le Saux O, Ray-Coquard I and Labidi-Galy SI: Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. Semin Cancer Biol. 77:127–143. 2021. View Article : Google Scholar |
